Human induced pluripotent stem cells (hiPSC) and their derivatives hold the potential to revolutionize the cell therapy field.

Pioneering attempts at large-scale manufacturing of hiPSC for clinical use have been exploiting existing bioreactor systems.

Relating the quality of hiPSC-based products to critical features and process parameters of existing bioreactors appears the best approach for the future development of hiPSC-tailored culture systems and manufacturing processes.